Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Sir_Holleron May 01, 2015 1:44pm

150 Views

Post# 23685910

RE:RE:A multi-billionaire and his friends:

"Do you think there will be some arm wrestling between him and Ken Dart? :)"

Most of the arm wrestling between them may now be over given the framework agreement, however until the deal is nailed down they will still be at it.

Didn't RVX say they were in talks with a number of parties however, including for a potenial takeover? The real arm wrestling may be behind the scenes with someone else.

Bullboard Posts

How one company is disrupting PoC testing